287 related articles for article (PubMed ID: 37093453)
1. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S
J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453
[TBL] [Abstract][Full Text] [Related]
2. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Cena H; Chiovato L; Nappi RE
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
Bader S; Bhatti R; Mussa B; Abusanana S
Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
[TBL] [Abstract][Full Text] [Related]
4. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
Tzotzas T; Karras SN; Katsiki N
Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Ma R; Ding X; Wang Y; Deng Y; Sun A
Medicine (Baltimore); 2021 Jun; 100(23):e26295. PubMed ID: 34115034
[TBL] [Abstract][Full Text] [Related]
7. Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.
Liao M; Li X; Zhang H; Zhou L; Shi L; Li W; Shen R; Peng G; Zhao H; Shao J; Wang X; Sun Z; Zheng H; Long M
Endocrine; 2024 Jan; 83(1):227-241. PubMed ID: 37653215
[TBL] [Abstract][Full Text] [Related]
8. Therapy of obesity in women with PCOS using GLP-1 analogues - benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia].
Baranowska-Bik A
Endokrynol Pol; 2022; 73(3):627-643. PubMed ID: 36059178
[TBL] [Abstract][Full Text] [Related]
9. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
Siamashvili M; Davis SN
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1081-1089. PubMed ID: 34015974
[No Abstract] [Full Text] [Related]
10. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome.
Bednarz K; Kowalczyk K; Cwynar M; Czapla D; Czarkowski W; Kmita D; Nowak A; Madej P
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457152
[TBL] [Abstract][Full Text] [Related]
11. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
[TBL] [Abstract][Full Text] [Related]
12. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
Lamos EM; Malek R; Davis SN
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):401-408. PubMed ID: 28276778
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
Niafar M; Pourafkari L; Porhomayon J; Nader N
Arch Gynecol Obstet; 2016 Mar; 293(3):509-15. PubMed ID: 26660657
[TBL] [Abstract][Full Text] [Related]
15. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
Jensterle M; Kocjan T; Kravos NA; Pfeifer M; Janez A
Endocr Res; 2015; 40(3):133-8. PubMed ID: 25330463
[TBL] [Abstract][Full Text] [Related]
16. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons.
Papaetis GS; Kyriacou A
Adv Clin Exp Med; 2022 Nov; 31(11):1265-1274. PubMed ID: 35951627
[TBL] [Abstract][Full Text] [Related]
18. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
[TBL] [Abstract][Full Text] [Related]
20. Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.
Torres Fernandez ED; Huffman AM; Syed M; Romero DG; Yanes Cardozo LL
Endocrinology; 2019 Dec; 160(12):2787-2799. PubMed ID: 31593246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
